IMUGENE LIMITED — AGM Information 2019

Nov 7, 2019

==> picture [205 x 88] intentionally omitted <==

Imugene AGM

8[th] November 2019

Experienced management team which have significant clinical development expertise

==> picture [93 x 93] intentionally omitted <==

==> picture [93 x 93] intentionally omitted <==

Dr Mark Marino SAN DIEGO, USA

Chief Medical Officer

• 28+ years of experience in drug development

• Former CMO of Cytori, Head of Clinical Pharmacology at Eisai and Roche, Head of R&D at Mannkind and VP Clinical Development at Daiichi

==> picture [362 x 293] intentionally omitted <==

==> picture [92 x 93] intentionally omitted <==

Dr Anthony Good SYDNEY, AU

==> picture [86 x 87] intentionally omitted <==

VP of Clinical Research

• 20+ years experience in global clinical development

• Integral to the development of significant new medicines including Viagra, Revatio, Lipitor, and Somavert

• Ex Pfizer Global Research and Development, Ex Covance Clinical Services

==> picture [121 x 51] intentionally omitted <==

Dr Nick Ede

MELBOURNE, AU

Chief Technology Officer

• 25+ years peptide vaccine and drug development

• Former CEO Adistem and CEO of Mimotopes , VP Chemistry Chiron (now Novartis), Research Fellow CRC Vaccine Technology

Bonnie Nixon

SYDNEY, AU

Project Manager

• 5+ years of oncology experience

• across Phase I – IV clinical trials

• Ex North America Study Manager at Genentech, Ex Roche Clinical Operations Australia

Imugene has a team with oncology drug development experience

2

- 2018 2019 Year in Review

==> picture [121 x 51] intentionally omitted <==

• Successful integration of Ohio Sate University B Cell immunotherapies

• Commencement of PD-1 manufacturing

• Successful Pre-IND FDA meeting for guidance for PD1-Vaxx Clinical Development Plan

• Met endpoints in Phase 1B HER-Vaxx gastric study

• First Patient Dosed in HER-Vaxx Phase 2 Study

• Leading international life science experts join the IMU Board : Dr. Russell and Dr. Eckstein

• Scientific Advisory Board (SAB) enhanced with appointments of Professors Kaumaya, Saab, & Caligiuri

• Proposed acquisition of City of Hope CF33 oncolytic virus

• Proposed new OV SAB to be Chaired by Prof Yuman Fong

3

HER-Vaxx PUBLICATIONS in MAJOR CANCER CONFERENCES

ASCO

==> picture [44 x 13] intentionally omitted <==

----- Start of picture text -----

AACR
----- End of picture text -----

ESMO-GI

==> picture [208 x 249] intentionally omitted <==

==> picture [203 x 249] intentionally omitted <==

==> picture [207 x 249] intentionally omitted <==

ESMO-GI 2019

ASCO 2019

AACR 2019

A Phase 1b study of IMU-131 HER2/NEU peptide vaccine plus chemotherapy in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5- fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/neu overexpressing advanced cancer of the stomach

A Phase 1B study of IMU-131 HER2/NEU peptide vaccine plus chemotherapy in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

==> picture [121 x 51] intentionally omitted <==

ESMO

==> picture [205 x 249] intentionally omitted <==

ESMO-2019

Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5- fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/neu overexpressing advanced gastric cancer

4

PD1-Vaxx PUBLICATIONS MAJOR CANCER CONFERENCES

==> picture [44 x 13] intentionally omitted <==

----- Start of picture text -----

AACR
----- End of picture text -----

ESMO

==> picture [206 x 249] intentionally omitted <==

==> picture [205 x 249] intentionally omitted <==

ESMO-2019

AACR 2019

Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line

Antitumor activity and safety of a novel PD1 vaccine (PD1-Vaxx) alone and in combination with two chimeric HER-2 peptide vaccine (B-Vaxx) in syngeneic Balb/c mice and canines

==> picture [121 x 51] intentionally omitted <==

5

==> picture [121 x 51] intentionally omitted <==

Proposed Vaxinia CF33 Oncolytic Virus (OV) Acquisition

• OVs are a promising area of immuno-oncology and of focused interest to Big Pharma

• Vaxinia offers IMU the opportunity of entering the OV field at a relatively advanced stage of development

• Two clinical trials are forecast to commence in 2020: one at City of Hope and the

• other across multiple centres in the U.S.

• One GMP virus lot completed; the other is near final in completion.

• The inventor Professor Yuman Fong is an internationally recognized surgeon, a

• researcher, a scholar, a true renaissance man.

• The acquisition of Vaxinia brings with it the core experienced clinical development team of Viralyics – which sold to Merck last year for A$502 million

==> picture [165 x 155] intentionally omitted <==

==> picture [227 x 72] intentionally omitted <==

6

CF33 MANAGEMENT TEAM

==> picture [121 x 51] intentionally omitted <==

==> picture [806 x 434] intentionally omitted <==

----- Start of picture text -----

Paul Hopper
Executive Chairman
L e s l i e C h o n g
M D & C E O
Dr Len Post Mark Grose Dr Evan Siegal
Dr Seymour Fein Dr Mike White
Dr Nick Ede Senior Scientific Clinical Trials IND Lead on Vaxinia
Medical Monitor Biostatistician
Advisor Manager IND Submission
Former Clinical Former IND Leader
Former Director Former Medical Former Viralytics
CMC Expertise Trials Manager at on Viralytics IND
Biovex Monitor at Viralytics Biostatistician
Viralytics Submission
Practical Clinical
Former Director
(Lisa Guttman and
Viralytics
Leslie Guerreiro)
----- End of picture text -----

I n v e s t o r P r e s e n t a t i o n N o v 2 0 1 9

7

MULTIPLE NEAR & MEDIUM TERM VALUE INFLECTION POINTS

==> picture [121 x 51] intentionally omitted <==

==> picture [946 x 210] intentionally omitted <==

Next 12 months

8

Financial Summary

Public Market Overview
Share Price1	A$0.023
Market Capitalisation2	A$83.1M
Cash equivalents (30 Sep 19 +R&D rebate)	A$17.8M
Enterprise Value	A$65.3M

Top 5 Shareholders (as at October 2019)

National Nominees Limited	5.6%
Dr. Nicholas Smith	3.3%
Paul Hopper	2.1%
HSBC Custody Nominees (Australia)	1.8%
Sarah Cameron	1.7%

==> picture [121 x 51] intentionally omitted <==

Share Price Performance (last 6 months)

==> picture [473 x 318] intentionally omitted <==

----- Start of picture text -----

IMU announced EGM and
IMU announced proposed Clinical Development of
acquistion of CF33 CF33
----- End of picture text -----

Note:

1. As of 29 October 2019

2. Market capitalization calculations based on ordinary shares (3.61bn) only and excludes the dilutive impact of options outstanding (652m)

I n v e s t o r P r e s e n t a t i o n

9

==> picture [205 x 88] intentionally omitted <==

Leslie Chong Managing Director & CEO leslie.chong@imugene.com +61 458 040 433